Global Immune Technologies Inc. - FORM 10-K - XML - IDEA: XBRL DOCUMENT - November 19, 2012



Attached files
FileFilename
EX-31.2 - EXHIBIT 31.2 - Global Immune Technologies Inc.v328258_ex31-2.htm
EX-32.1 - EXHIBIT 32.1 - Global Immune Technologies Inc.v328258_ex32-1.htm
EX-31.1 - EXHIBIT 31.1 - Global Immune Technologies Inc.v328258_ex31-1.htm
XML - IDEA: XBRL DOCUMENT - Global Immune Technologies Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Global Immune Technologies Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Global Immune Technologies Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Global Immune Technologies Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Global Immune Technologies Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Global Immune Technologies Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Global Immune Technologies Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Global Immune Technologies Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Global Immune Technologies Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Global Immune Technologies Inc.R2.htm
10-K - FORM 10-K - Global Immune Technologies Inc.v328258_10k.htm
XML - IDEA: XBRL DOCUMENT - Global Immune Technologies Inc.R5.htm
EXCEL - IDEA: XBRL DOCUMENT - Global Immune Technologies Inc.Financial_Report.xls
EX-32.2 - EXHIBIT 32.2 - Global Immune Technologies Inc.v328258_ex32-2.htm
v2.4.0.6
Statements of Operations (USD $)
12 Months Ended 156 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Mar. 31, 2012
General & administrative expenses:      
Management fees $ 30,000 $ 30,000 $ 227,383
Professional fees 32,797 39,876 517,495
Travel & entertainment 0 0 3,498
Transfer agent & filing fees 0 4,656 7,656
Foreign currency gain (loss) 0 0 758
Rent expense 0 0 74,177
General administration 2,345 20,956 336,235
Office supplies and sundry expenses 0 0 121,349
Consulting Expense 0 76,945 202,443
Net loss before other income (expense) (65,142) (172,433) (1,490,994)
Deferred expenses written off 0 0 (318,404)
Forgiveness of debt 0 0 145,450
Gain on sale of mineral rights 0 0 110,859
Legal settlement 0 0 129,031
Other write offs 0 0 (607,353)
Translation adjustment 0 0 187,015
Net loss from continuing operations (65,142) (172,433) (2,218,426)
Net loss from discontinued operations 0 0 (193,075)
Net loss $ (65,142) $ (172,433) $ (2,411,501)
Basic & diluted loss per share $ 0.00 $ (0.01)  
Weighted average of common shares outstanding 23,890,153 18,138,352  

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA



This web site and associated pages are not associated with, endorsed by, or sponsored by Global Immune Technologies Inc. and has no official or unofficial affiliation with Global Immune Technologies Inc.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.